JP2011522824A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522824A5 JP2011522824A5 JP2011512608A JP2011512608A JP2011522824A5 JP 2011522824 A5 JP2011522824 A5 JP 2011522824A5 JP 2011512608 A JP2011512608 A JP 2011512608A JP 2011512608 A JP2011512608 A JP 2011512608A JP 2011522824 A5 JP2011522824 A5 JP 2011522824A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- composition
- administered
- amino acid
- natriuretic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5957608P | 2008-06-06 | 2008-06-06 | |
| US61/059,576 | 2008-06-06 | ||
| PCT/US2009/046095 WO2009149161A2 (en) | 2008-06-06 | 2009-06-03 | Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522824A JP2011522824A (ja) | 2011-08-04 |
| JP2011522824A5 true JP2011522824A5 (https=) | 2013-05-23 |
Family
ID=41398834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512608A Pending JP2011522824A (ja) | 2008-06-06 | 2009-06-03 | キメラナトリウム利尿ポリペプチドおよび心臓リモデリングを阻害するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110152194A1 (https=) |
| EP (1) | EP2303305A4 (https=) |
| JP (1) | JP2011522824A (https=) |
| KR (1) | KR20110020903A (https=) |
| CN (1) | CN102143757A (https=) |
| AU (1) | AU2009256222A1 (https=) |
| CA (1) | CA2727085A1 (https=) |
| WO (1) | WO2009149161A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| US8455438B2 (en) | 2008-12-29 | 2013-06-04 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides for reducing or preventing restenosis |
| US20120108514A1 (en) | 2009-07-09 | 2012-05-03 | University Of Iowa Research Foundation | Long acting atrial natriuretic peptide (la-anp) and methods for use thereof |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| EP2678028A2 (en) * | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
| US20120277155A1 (en) * | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| CN103906761B (zh) | 2011-08-30 | 2016-12-21 | 梅约医学教育与研究基金会 | 利钠多肽 |
| EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| WO2013103896A1 (en) | 2012-01-06 | 2013-07-11 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| US11312758B2 (en) * | 2016-08-18 | 2022-04-26 | National University Of Singapore | Peptides with vasodilatory and/or diuretic functions |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| EP4117692A4 (en) * | 2020-03-13 | 2024-05-01 | Mayo Foundation for Medical Education and Research | ASSESSMENT AND TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
| US12427185B2 (en) | 2023-09-05 | 2025-09-30 | E-Star Biotech, LLC | Formulations of MANP and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4161521A (en) * | 1975-08-08 | 1979-07-17 | Merck & Co., Inc. | Somatostatin analogs |
| US4757048A (en) * | 1985-11-05 | 1988-07-12 | Biotechnology Research Associates J.V. | Synthetic analogs of atrial natriuretic peptides |
| US4935492A (en) * | 1987-12-24 | 1990-06-19 | California Biotechnology Inc. | Cyclic analogs of atrial natriuretic peptides |
| AU5043900A (en) * | 1999-05-24 | 2000-12-12 | Mayo Foundation For Medical Education And Research | Adenovirus vectors encoding brain natriuretic peptide |
| US6407211B1 (en) * | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| EP1720562A4 (en) * | 2004-01-15 | 2009-10-28 | Scios Inc | METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE |
| US20070042957A1 (en) * | 2005-08-19 | 2007-02-22 | Mayo Foundation For Medical Education And Research | Type v phosphodiesterase inhibitors and natriuretic polypeptides |
| US7803901B2 (en) * | 2005-09-16 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Polypeptides with natriuresis activity |
| CN101501067B (zh) * | 2006-08-08 | 2013-01-16 | 梅约医学教育与研究基金会 | 利尿和利尿钠的多肽 |
| US8283318B2 (en) * | 2006-09-08 | 2012-10-09 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| CN101541957B (zh) * | 2007-07-20 | 2013-08-14 | 梅约医学教育与研究基金会 | 利尿钠多肽 |
| US8741842B2 (en) * | 2008-07-02 | 2014-06-03 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic polypeptides with unique pharmacologic profiles |
| US8642550B2 (en) * | 2008-10-24 | 2014-02-04 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides without hypotensive inducing capability |
| US8455438B2 (en) * | 2008-12-29 | 2013-06-04 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides for reducing or preventing restenosis |
| WO2010129655A2 (en) * | 2009-05-05 | 2010-11-11 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides having mutations within their disulfide rings |
| US20120108514A1 (en) * | 2009-07-09 | 2012-05-03 | University Of Iowa Research Foundation | Long acting atrial natriuretic peptide (la-anp) and methods for use thereof |
-
2009
- 2009-06-03 WO PCT/US2009/046095 patent/WO2009149161A2/en not_active Ceased
- 2009-06-03 CN CN2009801289321A patent/CN102143757A/zh active Pending
- 2009-06-03 US US12/996,500 patent/US20110152194A1/en not_active Abandoned
- 2009-06-03 EP EP09759320A patent/EP2303305A4/en not_active Withdrawn
- 2009-06-03 KR KR1020117000303A patent/KR20110020903A/ko not_active Withdrawn
- 2009-06-03 JP JP2011512608A patent/JP2011522824A/ja active Pending
- 2009-06-03 AU AU2009256222A patent/AU2009256222A1/en not_active Abandoned
- 2009-06-03 CA CA2727085A patent/CA2727085A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522824A5 (https=) | ||
| JP2016516016A5 (https=) | ||
| JP2023511358A5 (https=) | ||
| JP2014507442A5 (https=) | ||
| US9314507B2 (en) | Methods of treatment of heart failure with natriuretic peptides | |
| CN103402542B (zh) | 恶性肿瘤转移抑制用药物 | |
| JP2017531613A5 (https=) | ||
| US10336803B2 (en) | Insulin secreting polypeptides | |
| JP2017500316A5 (https=) | ||
| KR101627008B1 (ko) | 대동맥 섬유증을 치료하기 위한 조성물 및 방법 | |
| Kikuchi et al. | Usefulness of carperitide for the treatment of refractory heart failure due to severe acute myocardial infarction | |
| Lee et al. | Designer natriuretic peptides | |
| Zhang et al. | Effects of angiotensin converting enzyme inhibitor, angio-tensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats | |
| EP3500592B1 (en) | Peptides with vasodilatory and/or diuretic functions | |
| Cantú et al. | Clinical aspects of c-type natriuretic peptide on the cardiovascular system | |
| Sasaoka et al. | Low dose carperitide (alpha-hANP) administration is effective for preventing worsening renal function (WRF) and long-term renal protection | |
| CN103764165A (zh) | 组合利尿钠肽受体gc-a激动剂以及gc-b激动剂而成的用于防止恶性肿瘤恶化的药品 | |
| CN104208660B (zh) | 低分子量碱性成纤维细胞生长因子lmw fgf2的应用 | |
| Banyś et al. | Psychiatric manifestations in a patient after surgical management of aortic stenosis of systemic lupus erythematosus | |
| Lim et al. | Sustained delivery of a novel natriuretic peptide for three weeks with in situ polymer precipitation delivery system | |
| Lin et al. | e0160 Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure and renal protective effect | |
| Lee et al. | Neurohormonal Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide, in the Normal Dog | |
| Burnett | Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide: NPA7 | |
| Mizuno et al. | The effect of long-term angiotensin receptor blocker administration on improvement in diastolic function in hypertensive patients with diastolic dysfunction | |
| Kim et al. | Expression of Natriuretic Peptide mRNAs in Isoproterenol-Induced Cardiac Hypertrophy in Rats |